DGIdb - NINTEDANIB Drug Record

NINTEDANIB chembl:CHEMBL502835 ApprovedAntineoplastic

Alternate Names:

VARGATEF
BIBF1120
NINTEDANIB
OFEV
BIBF-1120
INTEDANIB
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
OFEV®
VARGATEF®
BIBF 1120
drugbank:09079
chembl:CHEMBL502835
chemidplus:656247-17-5
rxcui:1592737
pubchem.compound:9809715

Drug Info:

Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Categories	antifibrotic agents
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates (strength unknown)
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	kinase inhibitor
Drug Categories	oct1 inhibitors
Drug Categories	oct1 substrates
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	tyrosine kinase inhibitors
Drug Categories	ugt1a1 substrates

(7 More Sources)

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

NINTEDANIB FGFR2

Interaction Score: 0.47

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

PMIDs:
18559524 22238366 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology
NINTEDANIB FGFR3

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
22238366 18559524 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology
NINTEDANIB CFLAR

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
NINTEDANIB PDGFRA

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
31016670 18559524

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology
NINTEDANIB FGFR1

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
18559524 22238366 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology TTD
NINTEDANIB FGR

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB PDGFRB

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology
NINTEDANIB FLT1

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
18559524 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology
NINTEDANIB LYN

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC DrugBank
NINTEDANIB FLT4

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
18559524 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology
NINTEDANIB KDR

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name BIBF-1120,Vargatef

Notes

PMIDs:
18559524 19522465 31016670

Sources:
TALC DTC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology
NINTEDANIB FGFR4

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial GuideToPharmacology
NINTEDANIB LCK

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC DrugBank
NINTEDANIB HCK

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB SRC

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC DrugBank
NINTEDANIB FLT3

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
18559524 31016670

Sources:
DrugBank TTD
NINTEDANIB FRK

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB BLK

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB FYN

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
NINTEDANIB AKT1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18559524

Sources:
DTC
NINTEDANIB RET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Pan-TK inhibitor

Alteration RET__.

PMIDs:
None found

Sources:
CGI
NINTEDANIB YES1

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

DrugBank: DB09079

Version: 5.1.7

Alternate Names:

NINTEDANIB DrugBank Drug Name

656247-17-5 CAS Number

Ofev Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories antifibrotic agents

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

MyCancerGenome: NINTEDANIB
- Version: 20-Jun-2017
Alternate Names:

BIBF1120 Development Name

NINTEDANIB Generic Name

VARGATEF Trade Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: NINTEDANIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

DTC: NINTEDANIB

Version: 02-September-2020

Alternate Names:

CHEMBL502835 ChEMBL Drug ID

Drug Info:

Publications:

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Roth GJ et al., 2009, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)., J Med Chem

JAX-CKB: Nintedanib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
TALC: NINTEDANIB
- Version: 12-May-2016
Alternate Names:

NINTEDANIB Primary Drug Name

VARGATEF Drug Trade Name

BIBF 1120 Drug Synonym

Drug Info:

Publications:
TTD: Intedanib
- Version: 2020.06.01
Alternate Names:

D09HNV TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178102559
- Version: 29-September-2020
Alternate Names:

NINTEDANIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL502835
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
CGI: Nintedanib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: NINTEDANIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Trial Name	BIBF-1120,Vargatef
Novel drug target	Established target
Notes

Response Type	resistant
Indication/Tumor Type	urinary bladder cancer
Evidence Type	Actionable

Notes
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

NINTEDANIB	DrugBank Drug Name
656247-17-5	CAS Number
Ofev	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	antifibrotic agents

BIBF1120	Development Name
NINTEDANIB	Generic Name
VARGATEF	Trade Name

NINTEDANIB	Primary Drug Name
VARGATEF	Drug Trade Name
BIBF 1120	Drug Synonym

NINTEDANIB Drug Record

NINTEDANIB chembl:CHEMBL502835 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name BIBF-1120,Vargatef Novel drug target Established target Notes

PMIDs: 18559524 22238366 31016670

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type resistant Indication/Tumor Type urinary bladder cancer Evidence Type Actionable

PMIDs: 22238366 18559524 31016670

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 31016670 18559524

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 18559524 22238366 31016670

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

PMIDs: 31016670 18559524

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

PMIDs: 18559524 31016670

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 18559524 31016670

Sources: TALC DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 18559524 31016670

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name BIBF-1120,Vargatef Notes

PMIDs: 18559524 19522465 31016670

Sources: TALC DTC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 18559524 31016670

Sources: TALC DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 18559524 31016670

Sources: TALC DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 18559524 31016670

Sources: DrugBank TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Notes

PMIDs:
18559524 22238366 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
22238366 18559524 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
31016670 18559524

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
18559524 22238366 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB GuideToPharmacology TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
18559524 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
18559524 31016670

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name BIBF-1120,Vargatef

Notes

PMIDs:
18559524 19522465 31016670

Sources:
TALC DTC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
18559524 31016670

Sources:
DrugBank TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

n/a

PMIDs:
18559524

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Pan-TK inhibitor

Alteration RET__.

PMIDs:
None found